On March 1, the U.S. Food and Drug Administration (FDA) approved Odactra, the first allergen extract to be administered sublingually to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in people 18 through 65 years of age. Read more
FDA approves extract for house dust mite allergic rhinitis
Most Recent Content
For Nurse Practitioners
Will Omicron Be More Contagious Than Delta?
If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...
